REGN-COV2
Medicinal
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed... Wikipedia
AHFS/Drugs.com: Monograph
Imdevimab: Monoclonal antibody against spike protein of SARS-CoV-2
Routes of administration: Intravenous, subcutaneous injection
People also ask
What are the brand names for casirivimab imdevimab?
What class of drug is casirivimab?
What is casirivimab and imdevimab side effects?
How do you use casirivimab and imdevimab?
The authorized dosage is 600 mg of casirivimab and 600 mg of imdevimab administered by subcutaneous injection or together as a single intravenous infusion as ...
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19.
600 mg/600 mg dose · 50-mL bag: 180 mL/hr (minimum time: 20 min) · 100-mL bag: 310 mL/hr (minimum time: 23 min) · 150-mL bag: 310 mL/hr (minimum time: 33 min) ...
Oct 30, 2021 · Casirivimab/imdevimab reduced viral load in non-hospitalized patients with SARS-COV-2 infection in an ongoing, randomized, double-blind, placebo ...
Nov 21, 2020 · Casirivimab and imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block ...
The recommended dose of casirivimab is 600 mg along with imdevimab 600 mg. In studies, doses up to 8 g (4000 mg of each drug) have been administered without ...
Due to the high frequency of the Omicron variant, REGEN-COV (casirivimab and imdevimab) is not currently authorized in any U.S. region. Therefore, REGEN-COV ...
Nov 8, 2021 · New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19.
Dec 9, 2021 · Casirivimab and imdevimab are a combination of two recombinant human antibodies that targets a different part of the spike protein, the part of ...
Related searches